Long-Term Varenicline + Short-Term Varenicline
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Tobacco Use Disorder
Conditions
Tobacco Use Disorder, Opioid-use Disorder
Trial Timeline
Oct 25, 2018 → Apr 24, 2024
NCT ID
NCT03365362About Long-Term Varenicline + Short-Term Varenicline
Long-Term Varenicline + Short-Term Varenicline is a approved stage product being developed by Pfizer for Tobacco Use Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT03365362. Target conditions include Tobacco Use Disorder, Opioid-use Disorder.
What happened to similar drugs?
6 of 9 similar drugs in Tobacco Use Disorder were approved
Approved (6) Terminated (3) Active (2)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03365362 | Approved | Completed |
Competing Products
20 competing products in Tobacco Use Disorder